Subacute cutaneous lupus erythematosus with melanocyte elimination induced by pembrolizumab

J Dermatol. 2020 Jun;47(6):e217-e219. doi: 10.1111/1346-8138.15316. Epub 2020 Mar 15.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged, 80 and over
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Autoantibodies / blood
  • Autoantibodies / immunology
  • Autoantigens / immunology
  • Facial Neoplasms / drug therapy
  • Facial Neoplasms / immunology
  • Facial Neoplasms / pathology
  • Humans
  • Immune Checkpoint Inhibitors / adverse effects*
  • Lupus Erythematosus, Cutaneous / chemically induced
  • Lupus Erythematosus, Cutaneous / diagnosis*
  • Lupus Erythematosus, Cutaneous / drug therapy
  • Lupus Erythematosus, Cutaneous / immunology
  • Male
  • Melanocytes / drug effects*
  • Melanocytes / immunology
  • Melanocytes / pathology
  • Melanoma / drug therapy
  • Melanoma / immunology
  • Melanoma / secondary
  • Prednisolone / therapeutic use
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors
  • Programmed Cell Death 1 Receptor / immunology
  • RNA, Small Cytoplasmic / immunology
  • Ribonucleoproteins / immunology
  • Skin / drug effects
  • Skin / immunology
  • Skin / pathology
  • Skin Neoplasms / drug therapy
  • Skin Neoplasms / immunology
  • Skin Neoplasms / pathology

Substances

  • Antibodies, Monoclonal, Humanized
  • Autoantibodies
  • Autoantigens
  • Immune Checkpoint Inhibitors
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor
  • RNA, Small Cytoplasmic
  • RO60 protein, human
  • Ribonucleoproteins
  • Prednisolone
  • pembrolizumab